Screened for eligibility (details of non-inclusion not available)

Randomization

- Sulfadoxine pyrimethamine monotherapy (n=199)
- Artesunate plus sulfadoxine-pyrimethamine (n=212)

Follow-up

- Lost to follow-up (n=23, 11.6%)
- Withdrawn due to AE (n=1, 0.5%)

Total followed to study endpoint (n=175, 87.9%)

- Excluded from analyses (Day 0 parasite data lost) (n=1, 0.5%)

Clinical/Parasitological Response

Total included (n=174, 87.4%)

Survival Analysis

Total (censored if lost to follow-up, withdrawn or re-infected) (n=198, 99.5%)

Total included (n=182, 85.8%)

Total (censored if lost to follow-up, withdrawn or re-infected) (n=210, 99.1%)